SK pharmteco, a global contract development and manufacturing organization serving the pharmaceutical industry, today announced that David Lowndes will be appointed as Chief Operating Officer. David will lead the company’s global Supply Chain, Quality, Regulatory Affairs, R&D, IT/Digital, and Operational Excellence functions through a period of significant and sustained growth.
“After serving together on multiple Pharma company Boards of Directors, it is with pleasure to announce that David has agreed to join the SK pharmteco Leadership Team as Chief Operating Officer. David brings a wealth of experience across the pharmaceutical industry and will provide leadership to the patient-centric focus we continually strive for by ensuring functional excellence in everything we do,” shares Joerg Ahlgrimm, CEO of SK pharmteco.
David brings 38 years of experience and a track record of delivering world-class results across multiple corporate leadership roles. Most recently, he served on the Board of Directors of SK pharmteco and was a Senior Vice President at SHIRE Pharmaceuticals, where he oversaw multiple global functions.
“SK pharmteco is entering a period of exceptional growth, and I am excited to serve as a member of the Corporate Leadership Team driving our company to the next level. Our vision is to be the most trusted partner in the manufacture and testing of medicines and through this, benefit patients and society worldwide” shares David Lowndes, COO of SK pharmteco.
David holds a bachelor’s degree in Pharmacy from Cardiff University in Wales. He has served on numerous professional communities, including the Faculty of Supply Chain Management World, the Future of Healthcare Advisory Board – Supply Chain Management World, the Governance Committee/Xavier Integrity of Supply Initiative, and a member of the strategy committee at the FDA/Xavier Pharmalink conference.
About SK pharmteco
Headquartered in Rancho Cordova, California, SK pharmteco is a global CDMO and a subsidiary of SK Inc., the strategic investment company for SK Group, South Korea’s second-largest conglomerate. SK pharmteco was established in 2019 by consolidating highly complementary CDMO business operations. SK pharmteco has established a well-balanced business portfolio by engaging in small molecule & cell and gene therapy to capture both the robust and exponential growth of each market. Most recently, SK pharmteco became the second-largest shareholder of the Center for Breakthrough Medicines through its investment in March 2022. SK pharmteco currently operates eight global manufacturing sites in the United States, Europe, and South Korea, along with five R&D centers.
Additional information can be obtained by visiting our website at www.skpharmteco.com.
